Literature DB >> 10954915

The impact of the ovulatory cycle on cytokine production: evaluation of systemic, cervicovaginal, and salivary compartments.

L Al-Harthi1, D J Wright, D Anderson, M Cohen, D Matity Ahu, J Cohn, S Cu-Unvin, D Burns, P Reichelderfer, S Lewis, S Beckner, A Kovacs, A Landay.   

Abstract

To understand the impact of the menstrual cycle on immunologic parameters, we measured the level of cytokines and chemokines from plasma, cervicovaginal lavage (CVL), and saliva samples of 6 premenopausal women during the follicular and luteal phases of the ovulatory cycle. We demonstrate that the level of plasma interleukin-8 (IL-8) was 4-fold higher during the follicular phase than the luteal phase (p = 0.004), whereas plasma IL-1beta, IL-4, IL-6, IL-10, interferon-gamma (IFN-gamma), transforming growth factor-beta (TGF-beta), tumor necrosis factor-alpha (TNF-alpha), macrophage inflammatory protein-1alpha (MIP-1alpha), and TNF receptor II (TNFR II) were not altered during the ovulatory cycle. In the vaginal compartment, as measured from CVL samples, the levels of IL-6 and IL-1beta were both 5-fold higher in the follicular than the luteal phase (p = 0.0002 and 0.03, respectively). Salivary cytokine and chemokine samples were similar when measured during the luteal and the follicular phases. Additional analysis of lymphocyte subsets for phenotypic and functional markers indicated that they were not influenced by the ovulatory cycle. Collectively, these data suggest that IL-6, IL-8, and IL-1beta are differentially regulated during the ovulatory cycle.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10954915     DOI: 10.1089/10799900050116426

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  28 in total

1.  Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% StarPharma LTD 7013 gel (VivaGel) to assess expanded safety.

Authors:  Anna-Barbara Moscicki; Rupert Kaul; Yifei Ma; Mark E Scott; Ibrahim I Daud; Elizabeth A Bukusi; Stephen Shiboski; Anuradha Rebbapragada; Sanja Huibner; Craig R Cohen
Journal:  J Acquir Immune Defic Syndr       Date:  2012-02-01       Impact factor: 3.731

Review 2.  Guiding the vaginal microbicide trials with biomarkers of inflammation.

Authors:  Raina N Fichorova
Journal:  J Acquir Immune Defic Syndr       Date:  2004-10       Impact factor: 3.731

3.  Novel three dimensional human endocervix cultures respond to 28-day hormone treatment.

Authors:  Sevim Yildiz Arslan; Yanni Yu; Joanne E Burdette; Mary Ellen Pavone; Thomas J Hope; Teresa K Woodruff; J Julie Kim
Journal:  Endocrinology       Date:  2015-01-30       Impact factor: 4.736

4.  Comparison of Follicular and Luteal Phase Mucosal Markers of HIV Susceptibility in Healthy Women.

Authors:  Andrea Ries Thurman; Neelima Chandra; Nazita Yousefieh; Irina Zalenskaya; Thomas Kimble; Susana Asin; Christiane Rollenhagen; Sharon M Anderson; Betsy Herold; Pedro M M Mesquita; Nicola Richardson-Harman; Tina Cunningham; Jill L Schwartz; Gustavo F Doncel
Journal:  AIDS Res Hum Retroviruses       Date:  2016-02-10       Impact factor: 2.205

5.  Urinary cytokine and chemokine profiles across the menstrual cycle in healthy reproductive-aged women.

Authors:  Brian W Whitcomb; Sunni L Mumford; Neil J Perkins; Jean Wactawski-Wende; Elizabeth R Bertone-Johnson; Kristine E Lynch; Enrique F Schisterman
Journal:  Fertil Steril       Date:  2014-02-26       Impact factor: 7.329

6.  Human papillomavirus-specific antibody status in oral fluids modestly reflects serum status in human immunodeficiency virus-positive individuals.

Authors:  Jennifer E Cameron; Isaac V Snowhite; Anil K Chaturvedi; Michael E Hagensee
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

7.  Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: effects on markers of inflammation and innate immunity in cervicovaginal fluid.

Authors:  Deborah J Anderson; D'Nyce L Williams; Susan A Ballagh; Kurt Barnhart; Mitchell D Creinin; Daniel R Newman; Frederick P Bowman; Joseph A Politch; Ann C Duerr; Denise J Jamieson
Journal:  Am J Reprod Immunol       Date:  2009-02       Impact factor: 3.886

8.  Innate immunity in the vagina (Part II): Anti-HIV activity and antiviral content of human vaginal secretions.

Authors:  Mickey V Patel; Mimi Ghosh; John V Fahey; Christina Ochsenbauer; Richard M Rossoll; Charles R Wira
Journal:  Am J Reprod Immunol       Date:  2014-05-08       Impact factor: 3.886

9.  Colposcopically observed vascular changes in the cervix in relation to the hormonal levels and menstrual cycle.

Authors:  Smita N Joshi; Soma Das; Madhuri Thakar; Vikrant Sahasrabuddhe; B Kishore Kumar; Marianne Callahan; Christine Mauck
Journal:  J Low Genit Tract Dis       Date:  2008-10       Impact factor: 1.925

10.  To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers.

Authors:  Mary-Frances O'Connor; Julie E Bower; Hyong Jin Cho; J David Creswell; Stoyan Dimitrov; Mary E Hamby; Michael A Hoyt; Jennifer L Martin; Theodore F Robles; Erica K Sloan; Kamala S Thomas; Michael R Irwin
Journal:  Brain Behav Immun       Date:  2009-04-21       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.